Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation

被引：48

作者：

Ghadimi, Kamrouz ^{[1
,2
]}

Dombrowski, Keith E. ^{[3
]}

Levy, Jerrold H. ^{[1
,2
]}

Welsby, Ian J. ^{[1
,2
]}

机构：

[1] Duke Univ, Med Ctr, Div Cardiothorac Anesthesiol, Durham, NC USA

[2] Duke Univ, Med Ctr, Div Crit Care Med, Durham, NC USA

[3] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA

来源：

EXPERT REVIEW OF HEMATOLOGY | 2016年 / 9卷 / 02期

关键词：

Morpholines; Thiophenes; Andexanet alfa; Factor Xa inhibitors; Prothrombinase; Hemostasis; Thrombosis; Thrombin Generation; Apixaban; Rivaroxaban; PROTHROMBIN COMPLEX CONCENTRATE; VITAMIN-K; INTRACEREBRAL HEMORRHAGE; ORAL ANTICOAGULANTS; MANAGEMENT; RIVAROXABAN; GUIDELINES; WARFARIN; SOCIETY; PLASMA;

D O I：

10.1586/17474086.2016.1135046

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. The molecule is a recombinant protein analog of factor Xa that binds to Factor Xa inhibitors and antithrombin: LMWH complex but does not trigger prothrombotic activity. In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) was able to dose-dependently reverse Factor Xa inhibition and restore thrombin generation for the duration of drug administration. Further trials are underway to examine its safety and efficacy in the population of patients experiencing FXa inhibitor-related bleeding.

引用

页码：115 / 122

页数：8

共 32 条

[11] Crowther M, 2014, 24 C INT SOC THROMB
[12] Antidotes for Novel Oral Anticoagulants Current Status and Future Potential
Crowther, Mark
Crowther, Mark A.
[J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2015, 35 (08) : 1736 - 1745
[13] Crowther M, 2014, CIRCULATION, V130, P2116
[14] Reversal of drug-induced anticoagulation: old solutions and new problems
Dzik, Walter 'Sunny'
[J]. TRANSFUSION, 2012, 52 : 45S - 55S
[15] Enriquez A, 2015, ANTICOAGULATION REVE
[16] 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines
Ferraris, Victor A.
Brown, Jeremiah R.
Despotis, George J.
Hammon, John W.
Reece, T. Brett
Saha, Sibu P.
Song, Howard K.
Clough, Ellen R.
Shore-Lesserson, Linda J.
Goodnough, Lawrence T.
Mazer, C. David
Shander, Aryeh
Stafford-Smith, Mark
Waters, Jonathan
Baker, Robert A.
Dickinson, Timothy A.
FitzGerald, Daniel J.
Likosky, Donald S.
Shann, Kenneth G.
[J]. ANNALS OF THORACIC SURGERY, 2011, 91 (03) : 944 - 982
[17] Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Holbrook, Anne
Schulman, Sam
Witt, Daniel M.
Vandvik, Per Olav
Fish, Jason
Kovacs, Michael J.
Svensson, Peter J.
Veenstra, David L.
Crowther, Mark
Guyatt, Gordon H.
[J]. CHEST, 2012, 141 (02) : E152S - E184S
[18] Hollenbach S, 2013, EUR HEART J, V34, P24
[19] Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy -: Comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates
Huttner, Hagen B.
Schellinger, Peter D.
Hartmann, Marius
Koehrmann, Martin
Juettler, Eric
Wikner, Johannes
Mueller, Stephan
Meyding-Lamade, Uta
Strobl, Ralf
Mansmann, Ulrich
Schwab, Stefan
Steiner, Thorsten
[J]. STROKE, 2006, 37 (06) : 1465 - 1470
[20] Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers
Levi, M.
Moore, K. T.
Castillejos, C. F.
Kubitza, D.
Berkowitz, S. D.
Goldhaber, S. Z.
Raghoebar, M.
Patel, M. R.
Weitz, J. I.
Levy, J. H.
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (09) : 1428 - 1436

← 1 2 3 4 →